Abstract
BackgroundEarly treatment responses are important prognostic factors in childhood T-cell acute lymphoblastic leukemia (T-ALL) patients. The predictive values of early treatment responses in Chinese childhood T-ALL patients were still unknown.MethodsFrom January 2003 to December 2012, 74 consecutive patients aged ≤15 years with newly diagnosed T-ALL were treated with BCH-2003 protocol or CCLG-2008 protocol in the Department of Pediatric, Institute of Hematology and Blood Diseases Hospital in China. Predictive values of early treatment responses, including prednisone response, bone marrow morphology at day 15 and day 33 during induction chemotherapy, and minimal residual disease (MRD) monitored by flow cytometry after induction therapy (time point 1, TP1) and before consolidation therapy (time point 2, TP2), were analyzed.ResultsThe 5-year event free survival (EFS) and overall survival (OS) rates for these patients were 62.5 % (SE, 6.4) and 62.7 % (SE, 6.6), respectively. Prednisone poor responder was strongly associated with increased chance of induction failure (14.8 %) and decreased survival rate (5 year EFS rate, 51.1 % (SE, 10.5)). Patients with ≥25 % blast cells in bone marrow at day 15 were more likely to have an inferior outcome. 93.2 % of the T-ALL patients achieved complete remission at day 33 while patients with resistant disease all died of disease progression. MRD ≥10−2 at TP1 or MRD ≥10−3 at TP2 was significantly related to dismal prognosis. Risk groups classified by MRD at two time points could stratify patients into different groups: 29.0 % of the patients were MRD standard risk (MRD < 10−4 at both time points) with 3-year EFS rate of 100 %, 29.0 % were MRD high risk (MRD ≥10−2 at TP1 or MRD ≥10−2 at TP2) with 3-year EFS rate of 55.6 % (SE, 16.6) , and the rest of patients were defined as MRD intermediate risk with 3-year EFS rate of 85.7 % (SE, 13.2).ConclusionOur study demonstrated that MRD was the most powerful predictor of treatment outcome in childhood T-ALL patients and conventional morphological assessments of treatment response still played important roles in predicting treatment outcome and tailoring treatment intensity especially in countries with inadequate skills or financial resources for MRD monitoring.Electronic supplementary materialThe online version of this article (doi:10.1186/s12887-015-0390-z) contains supplementary material, which is available to authorized users.
Highlights
Treatment responses are important prognostic factors in childhood T-cell acute lymphoblastic leukemia (T-Acute lymphoblastic leukemia (ALL)) patients
Patients were stratified into intermediate risk (IR) and high risk (HR) groups according to cytogenetic aberration, prednisone response, bone marrow morphology at day 15 and 33, and minimal residual disease (MRD) levels (The details of stratification criteria and treatment protocols were described in Additional file 1: Table S1, S2, S3)
Ages ranged from 1 to 15 years with a median age of 9 years. 45 (60.8 %) patients presented with initial white blood cell (WBC) count ≥100 × 109/L. 29 (40.3 %) patients were classified as the intermediate risk (IR) group and 43 (59.7 %) patients were in the high risk (HR) group according to the risk stratifications. 27 (36.5 %) patients followed BCH-2003 protocol and 47 (63.5 %) were treated with CCLG-2008 protocol
Summary
Treatment responses are important prognostic factors in childhood T-cell acute lymphoblastic leukemia (T-ALL) patients. The predictive values of early treatment responses in Chinese childhood T-ALL patients were still unknown. During the last two decades, minimal residual disease (MRD) in childhood ALL had been proved to be a remarkable predictive factor and already become an integral part of risk stratifications in many long established leukemia groups [19,20,21,22,23,24]. A slower clearance of leukemia cells was found in T-ALL patients and MRD risk group classified by MRD levels at the end of induction and before consolidation therapy was identified to be the most powerful independent prognostic factor in T-ALL patients [32, 33]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.